Roivant Sciences (ROIV) Insider LP Sells $28M of Stock
Qvt Financial LP sold 800,000 shares of Roivant Sciences Ltd. for $27.64 million on June 29, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Qvt Financial LP sold 800,000 shares of Roivant Sciences Ltd. ($ROIV) at an average price of $34.55, worth about $27.64 million, on June 29, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ROIV is up 1.9% after 1 week, down 5.4% after 1 month and down 3.5% to date (from the $34.73 close on Jun 29, 2026).
ROIV
Roivant Sciences Ltd.
Key Points
- Qvt Financial LP sold 800,000 shares of Roivant Sciences at a price of $34.55, totaling a value of $27.64 million as of June 29, 2026.
- On the same date, Roivant Sciences stock closed at $35.39, having previously traded as high as $39.77.
- Mayukh Sukhatme, President & CIO at Roivant, sold 500,000 shares for $17.07 million just days before this transaction.
Get $ROIV trade alerts by text
We text you when insiders, Congress or big funds trade $ROIV. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Roivant Sciences Ltd. alert may contain errors. Disclosures
Qvt Financial Sells a Large Stake
Qvt Financial LP sold 800,000 shares of Roivant Sciences Ltd. (NasdaqGS: ROIV) on June 29, 2026 for approximately $27.64 million. The shares were sold at an average price of $34.55 each, with the transaction reflecting significant activity ahead of the company’s next earnings report in November.
Insider Buying and Selling at Roivant Sciences Ltd.
This sale adds to a series of insider transactions at Roivant. President & CIO Mayukh Sukhatme sold 500,000 shares just days earlier for about $17.07 million on June 25. Earlier on the same day, Sukhatme also exercised options for 500,000 shares at a much lower price of $3.85 each. Meanwhile, Eric Venker, President & CEO of Immunovant, executed buy and sell trades, maintaining significant insider participation in Roivant's stock activity.
Stock Performance Insights
As of the transaction date, Roivant Sciences was trading at $35.39, close to its 52-week high of $42.50. The stock has shown volatility, trading significantly above its 52-week low of $14.50. This recent insider selling comes as the stock had seen a rise from previous lows, signaling strategic adjustments by insiders amid changing market conditions.
Recent Earnings
In its latest reported quarter, Roivant Sciences generated $7.53 million in revenue but experienced a revenue decline of 33.5%. The company has not yet turned a profit, reporting an EPS of -0.47. The next earnings report is expected on November 9, 2026, which could provide more insight into its financial health and growth prospects.
What Roivant Sciences Ltd. Does
Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines and technologies. Their pipeline includes treatments for various autoimmune diseases and pulmonary hypertension, which are crucial areas in the healthcare sector.
What’s Next for Roivant
Investors will be watching Roivant closely, especially as the next earnings date approaches on November 9. Additionally, the recent insider selling may prompt discussions regarding the company’s future strategies and market performance. It's important to note that this 13F filing reflects past holdings and may not represent current positions.
Related Filing Alerts
Source: Qvt Financial LP's Form 4 filing on $ROIV (Jun 29, 2026). Find the original filing: ROIV Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts